Abstract
BackgroundSeveral studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothelial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation.MethodsThis study examined 50 patients who underwent a 9-month follow-up using optical coherence tomography (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion (MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow-up, we evaluated the percentage of uncovered struts and three-dimensional uniformity of neointimal distribution by calculating the mean neointimal thickness (NIT) within 360 equally-spaced radial sectors for every 1-mm cross-sectional OCT analysis, and assessed the incidence of major adverse cardiovascular events (MACE).ResultsWe evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coefficient β ± standard error = 0.267 ± 0.073 and 0.016 ± 0.003, t = 3.668 and 6.092, both P < 0.001, respectively). In multivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β ± standard error = 0.239 ± 0.093, P = 0.014) and the percentage of uncovered struts (coefficient β ± standard error = 0.019 ± 0.004, P < 0.001). Five lesions in four patients required target lesion revascularization (10.0 %) at a mean duration of 9 months after EES implantation. Compared to non-MACE cases, cases of MACE exhibited a significantly higher MAGE (99 vs. 68; P = 0.004), maximum NIT (580 vs. 330 µm; P = 0.002), and variability in NIT (100 vs. 65; P = 0.007), although there was no significant difference in these groups’ HbA1c levels.ConclusionsGlucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are receiving lipid-lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control.
Highlights
Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothe‐ lial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability
Glucose fluctuations may be an important target for secondary prevention after coronary stenting, which is independent of dyslipidemia control
Associations of optical coherence tomogra‐ phy (OCT) measurements with diabetic control markers and non‐glycemic metabolic variables Linear mixed effect models were used to explore the influence of different variables on variability in neointimal thickness (NIT) and the percentage of uncovered struts and to adjust for covariates
Summary
Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothe‐ lial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. We aimed to investigate the effects of glucose fluctuations on neointimal growth after everolimus-eluting stent (EES) implantation. Dyslipidemia, and especially high levels of low-density lipoprotein (LDL) cholesterol, has been recognized as one of the most important promoters of late-phase stent restenosis. A large number of clinical trials have reported the beneficial effects of statins for secondary prevention and improved all-cause mortality, as well as for lowering LDL cholesterol levels [1, 2]. The introduction of second-generation drug-eluting stents (DES), such as the everolimus-eluting stent (EES), has markedly reduced the incidence of early- and late-phase stent restenosis, the presence of DM is still associated with an increased risk of restenosis and poor clinical outcomes after percutaneous coronary intervention (PCI) [6, 7]. The detailed vascular responses to EES implantation among patients with impaired glucose metabolism has not been fully elucidated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
